| Subject: | FDA Announces Labeling Changes to the "RU-486 pill" Mifepristone (Mifeprex) |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 23 Nov 2004 - 10:00 am |
| The FDA published a statement announcing safety changes to the labeling requirements for the drug Mifepristone (Mifeprex) which is commonly known as the RU-486 pill, distributed by Danco Laboratories. The FDA noted there have been reports of the following from patients who have received Mifepristone:
Serious bacterial infection -Bleeding -Ectopic pregnancies that have ruptured -Death (including death from sepsis)
The drug Mifepristone was... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
Related MCN Products:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|